These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 25967739)

  • 1. Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.
    Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB
    Org Biomol Chem; 2015 Jun; 13(22):6299-312. PubMed ID: 25967739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
    Toscan CE; Failes T; Arndt GM; Lock RB
    J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
    Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
    Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
    Toscan CE; Jing D; Mayoh C; Lock RB
    Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
    Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB
    Cancer Cell; 2018 Dec; 34(6):906-921.e8. PubMed ID: 30537513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumvention of glucocorticoid resistance in childhood leukemia.
    Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
    Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of autophagy-related genes might contribute to glucocorticoid resistance in precursor B-cell-type acute lymphoblastic leukemia.
    Sarang Z; Gyurina K; Scholtz B; Kiss C; Szegedi I
    Eur J Haematol; 2016 Nov; 97(5):453-460. PubMed ID: 26947147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia.
    Zhang C; Chan KYY; Ng WH; Cheung JTK; Sun Q; Wang H; Chung PY; Cheng FWT; Leung AWK; Zhang XB; Lee PY; Fok SP; Lin G; Poon ENY; Feng JH; Tang YL; Luo XQ; Huang LB; Kang W; Tang PMK; Huang J; Chen C; Dong J; Mejstrikova E; Cai J; Liu Y; Shen S; Yang JJ; Yuen PMP; Li CK; Leung KT
    Haematologica; 2024 Sep; 109(9):2833-2845. PubMed ID: 38572553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
    Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
    Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
    Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia.
    Bhadri VA; Cowley MJ; Kaplan W; Trahair TN; Lock RB
    BMC Genomics; 2011 Nov; 12():565. PubMed ID: 22093874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
    Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T
    Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
    Nair RR; Piktel D; Geldenhuys WJ; Gibson LF
    Leuk Res; 2018 Sep; 72():59-66. PubMed ID: 30103201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.
    Zhou M; Wang T; Lai H; Zhao X; Yu Q; Zhou J; Yang Y
    Biochem Biophys Res Commun; 2015 Apr; 459(2):333-339. PubMed ID: 25735983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
    Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.
    Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB
    BMC Genomics; 2014 Jun; 15(1):416. PubMed ID: 24885906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of microRNAs in glucocorticoid‑resistant B‑cell precursor acute lymphoblastic leukemia.
    Sakurai N; Komada Y; Hanaki R; Morimoto M; Ito T; Nakato D; Hirayama M
    Oncol Rep; 2019 Aug; 42(2):708-716. PubMed ID: 31233193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
    Styczynski J; Kurylak A; Wysocki M
    Anticancer Res; 2005; 25(3B):2253-8. PubMed ID: 16158972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.